Sign Up | Log In | What is SocialPicks?

Eisai Co Ltd (ESALY) Trade Now » Rate ESALY - Discuss ESALY - Add to Watch List

This is a micro-cap stock and may be a target of manipulation. Always do your research!

SocialPicks Sentiment:

N/A

** not enough data to be rated

This Quarter's Sentiment:

All:

0.0%

Top:

0.0%

Rate ESALY:

Home

Analysis & Videos

Quotes

Bull or Bear

Discuss

ESALY Analysis & Videos »

... View All >

ESALY: Bull or Bear?

A New Index of Health Product Innovators ESALY

73%

A New Index of Health Product Innovators

The accompanying table includes statistics and all 23 companies in the ETF Innovators [ETFI] Global Health Innovators Index of companies with market caps over $250M which received FDA approval in the past 12 months for an original new drug product or medical device.

The index includes companies which get approvals for drugs or biological agents classified as new chemical entities (i.e. excluding all new formulations of existing drugs, generic drugs, and label extensions for existing products). Also, companies whi...

Continue reading »

By Mike Havrilla (+1.04% risk: moderate) 01/05/09

1 comment

R&D Leads to Higher Returns for Top 20 Health Innovators ESALY

73%

R&D Leads to Higher Returns for Top 20 Health Innovators

<> The accompanying table includes statistics and the top 20 rated companies in the ETF Innovators [ETFI] Global Health Innovators Index of companies with market caps over $250M which received FDA approval in the trailing 12-month period for either an original new drug product or medical device. The index includes companies which get approvals for drugs or biological agents classified as new chemical entities (i.e. excluding reformulations of existing drugs, generic drugs, and label extensions for exist...

Continue reading »

By Mike Havrilla (+1.04% risk: moderate) 11/23/08

5 comments

... View All >

People Bullish on ESALY

People Bearish on ESALY

Mike Havrilla

Principal

73%

over 2 years ago

... View All >

ROCK-STAR INVESTORS

Rank	Name	Sharpe Ratio	Avg Return	Followers
1	noshoes	21.10	+34.36%	531
2	Gerald Greene	18.14	+36.28%	286
3	stockmarketfunding.com	17.66	+23.07%	83
4	akiralegrand	13.47	+13.37%	69
5	anup2104	12.13	+132.16%	102

... more »

POPULAR STOCKS

Symbol	Company Name	Sentiment
TWX	Time Warner Inc
WMT	WalMart Stores Inc
INTC	Intel Corp
HPQ	HewlettPackard Company
BIDU	Baiducom Inc ADS
FNM	Fannie Mae

... more »

TODAY'S HEADLINES

LDK Solar's Growth Potential Offset by Gross Margin Pressure
by Paul Cheung (Zacks.com) about LDK

Cisco Systems Still a Wait and See
by Thomas Catino (Ant & Sons) about CSCO

The Merrill Lynch Diet: Starving Shareholders
by Zack Miller (BloggingStocks) about MER

Google Blows Q2: Multiple Compression to Continue
by Henry Blodget about GOOG

Stop Waiting for the Crash; Use a Regular Investment Plan
by Dan Caplinger (Fool.com) about SPY DJI

... more »

TODAY'S TOP PICKS

USO		Bullish on USO ... by jrmarketing2008
BWLD		Bullish on BWLD ... by jrmarketing2010
DO		Bullish on DO ... by jrmarketing2011
L		Bullish on L ... by jrmarketing2012
CMCSA		Bullish on CMCSA ... by jrmarketing2010

... more »

StreetInsider.com on ESALY

Abbott Japan and Eisai Announce Launch of Humira(R) Prefilled Syringe 20mg/0.4mL, a New Formulation for the Treatment of Juvenile Idiopathic Arthritisin Patients with Low Body Weight

Abbott Japan and Eisai Submit Application in Japan for Additional Indication of Humira(R)(adalimumab), a Fully Human Anti-TNF-alpha Monoclonal Antibody, for Inhibition of Structural Damage of Joints i

Eisai to Accelerate Late-Stage Clinical Development of New Drugs by Effectively Leveraging External Resources

Eisai to Launch New Selbelle(R) Tablets and New Selbelle(R) Fine Granules to Alleviate Post Meal Stomach Heaviness

Eisai Presents New Research on Epilepsy Pipeline, Portfolio at the 29th International Epilepsy Congress

Discussion Wall

+ Add

Be the first to start a discussion and earn 2 points.

... more »

More Resources

About Eisai Co Ltd - Answers.com

Historical Prices - Yahoo

Message Boards - BoardCentral.com

More Info: Yahoo | Google | Reuters

IN THE PRESS

None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.